You can access the original SEC filing by clicking here.
Ownership Summary Table
| Name | Sole Voting Power | Shared Voting Power | Sole Dispositive Power | Shared Dispositive Power | Aggregate Amount Owned Power | Percent of Class |
|---|---|---|---|---|---|---|
| Atlas Master Fund, Ltd | 224,506 | 224,506 | 224,506 | 1.05% | ||
| Atlas Global | 224,506 | 224,506 | 224,506 | 1.05% | ||
| Atlas Global Investments, Ltd | 224,506 | 224,506 | 224,506 | 1.05% | ||
| Atlas Institutional Fund | 224,506 | 224,506 | 224,506 | 1.05% | ||
| Atlas Institutional Fund, Ltd | 224,506 | 224,506 | 224,506 | 1.05% | ||
| Atlas Global Japan Unit Trust | 224,506 | 224,506 | 224,506 | 1.05% | ||
| Atlas Enhanced Master Fund, Ltd | 1,310,494 | 1,310,494 | 1,310,494 | 6.11% | ||
| Atlas Enhanced Fund | 1,310,494 | 1,310,494 | 1,310,494 | 6.11% | ||
| Atlas Enhanced Fund, Ltd | 1,310,494 | 1,310,494 | 1,310,494 | 6.11% | ||
| Atlas Fundamental Trading Master Fund, Ltd | 465,000 | 465,000 | 465,000 | 2.17% | ||
| Atlas Fundamental Trading Fund | 465,000 | 465,000 | 465,000 | 2.17% | ||
| Atlas Fundamental Trading Fund, Ltd | 465,000 | 465,000 | 465,000 | 2.17% | ||
| Balyasny Asset Management | 2,000,000 | 2,000,000 | 2,000,000 | 9.32% | ||
| Dmitry Balyasny | 2,000,000 | 2,000,000 | 2,000,000 | 9.32% |
Page 1 of 30 – SEC Filing
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
SUNESIS
PHARMACEUTICALS, INC.
(Name of Issuer)
COMMON STOCK
(Title of
Class of Securities)
867328700
(CUSIP Number)
June 23,
2017
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
☐ Rule 13d-1(b)
☒
Rule 13d-1(c)
☐ Rule 13d-1(d)
The
information required on the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 (Act) or otherwise subject to the liabilities of that section of
the Act but shall be subject to all other provisions of the Act (however, see the Notes).
13G Filing: Tiger Management and Ooma Inc (OOMA)
13G Filing: Biotechnology Value Fund LP and CytomX Therapeutics Inc (CTMX)
13G Filing: G2 Investment Partners Management and Datawatch Corp (DWCH)
13G Filing: Rutabaga Capital Management and Rutabaga Capital Management LLC
13G Filing: SQN Investors and Apptio Inc (APTI)
13G Filing: EJF Capital and Bank Of Commerce Holdings (BOCH)
